This document outlines exactly what the European Commission's revised Tobacco Products Directive means for brand...
AlpVision has signed a distribution contract for its Cryptoglyph® technology with Japanese IT and consulting service provider, Information Services International-Dentsu Ltd (ISID).
AlpVision president said: "ISID is a natural fit to support the development of the Japanese market and to help with the deployment of our Cryptoglyph technology, particularly on pharmaceutical packaging."
A joint venture between Dentsu Inc, one of the world’s largest independent advertising firms, and General Electric Company (GE), one of the leading blue-chip companies in the US, ISID offers a host of innovative IT solutions and brings extensive experience in product development and business operations consulting, particularly in the manufacturing and financial sectors.
In partnering with ISID, AlpVision not only hopes to respond to the increasing number of counterfeit Japanese brand-name pharmaceuticals sold in foreign countries, but also of fake medications appearing on the Japanese market, particularly those sold on websites operated by foreign drug sellers located in Hong Kong and Singapore (source).
AlpVision CEO Fred Jordan said: "Japanese pharmaceutical companies represent approximately 20% of the worldwide pharmaceutical turnover and offer therefore interesting development perspectives for AlpVision.
"The expansion of our business in Japan is as much a reflection of the increasing need for our services as it is of the continuing growth we’re experiencing in East Asia."
Printed using offset, flexographic and rotogravure printing presses, AlpVision Cryptoglyph is invisible to the naked eye and can be detected using a smartphone. Simple and industry proven, AlpVision’s Cryptoglyph technology has been deployed at large-scale among the Fortune 200 pharmaceutical companies in the world for more than a decade.
On April 3 2014, the European Commission published an updated version of the Tobacco Products...